Form 4: CalciMedica CEO A. Rachel Leheny Granted 77,625 Stock Options Following Shareholder Approval

CalciMedica, Inc. CEO A. Rachel Leheny was granted 77,625 employee stock options with an exercise price of $1.53 per share, following shareholder approval of an amendment to the company's 2023 Equity Incentive Plan.

Summary

• A. Rachel Leheny, Chief Executive Officer, Director, and 10% Owner of CalciMedica, Inc. (CALC), was granted 77,625 employee stock options.
• The options have an exercise price of $1.53 per share.
• The grant was approved by the Board of Directors on April 23, 2025, contingent on stockholder approval of an amendment to the Company's 2023 Equity Incentive Plan (Amended 2023 EIP).
• Stockholders approved the Amended 2023 EIP on June 24, 2025, making the option grant effective on this date.
• The options are immediately exercisable and have an expiration date of April 22, 2035.
• Following this transaction, A. Rachel Leheny beneficially owns 77,625 derivative securities directly.

Sentiment

Score: 6

Explanation: Slightly positive, as the grant of options to the CEO aligns her incentives with shareholder value, indicating continued commitment to the company's long-term success. It's a routine compensation event, not indicative of major news.

Positives

• The grant of stock options to the CEO aligns her interests with those of the shareholders, incentivizing long-term company performance.
• The option grant was made under an Equity Incentive Plan that received stockholder approval, indicating good corporate governance.

Future Outlook

The document primarily reports a past transaction and does not contain forward-looking statements regarding the company's financial performance or strategic direction, beyond the expiration date of the options in 2035.

Management Comments

• The option grant was approved by the Board of Directors of CalciMedica, Inc. on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction, common across all publicly traded companies. It reflects standard executive compensation practices within the biotechnology or pharmaceutical industry, where equity incentives are frequently used to align management interests with long-term shareholder value.

Corporate Governance

Related Party Transactions

• The grant of 77,625 employee stock options to A. Rachel Leheny, the Chief Executive Officer, Director, and 10% Owner, constitutes a related party transaction as it involves compensation to a key executive and significant shareholder.

Stakeholder Impact

• Shareholders: The option grant aligns the CEO's financial interests with the company's stock performance, potentially incentivizing decisions that enhance shareholder value.
• Employees: While specific to the CEO, such grants are part of broader equity incentive plans that can benefit other employees, fostering a culture of ownership and performance.

Next Steps

• The granted options are immediately exercisable, allowing the CEO to convert them into common stock at her discretion, subject to vesting schedules (if any, though not specified as a future event in this filing).

Key Dates

Keywords

CalciMedica, CALC, SEC Form 4, Stock Option Grant, CEO Compensation, Insider Transaction, Equity Incentive Plan, A. Rachel Leheny